000005151 001__ 5151
000005151 005__ 20180208231836.0
000005151 0247_ $$2pmid$$apmid:19353726
000005151 0247_ $$2DOI$$a10.1002/mds.22533
000005151 0247_ $$2WOS$$aWOS:000267511000009
000005151 037__ $$aPreJuSER-5151
000005151 041__ $$aeng
000005151 082__ $$a610
000005151 084__ $$2WoS$$aClinical Neurology
000005151 1001_ $$0P:(DE-HGF)0$$aStamelou, M.$$b0
000005151 245__ $$aNigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy
000005151 260__ $$aNew York, NY$$bWiley InterScience$$c2009
000005151 300__ $$a1170 - 1175
000005151 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000005151 3367_ $$2DataCite$$aOutput Types/Journal article
000005151 3367_ $$00$$2EndNote$$aJournal Article
000005151 3367_ $$2BibTeX$$aARTICLE
000005151 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000005151 3367_ $$2DRIVER$$aarticle
000005151 440_0 $$09683$$aMovement Disorders$$v24$$x0885-3185$$y8
000005151 500__ $$aThis project was part of the Brain Imaging Center West (BICW) supported by the German Federal Ministry for Education and Research (BMBF, grant 01 G19934 to K.Z.), the Deutsche Forschungsgemeinschaft (DFG, Klinische Forschergruppe 112 to A.B.; HO2402/6-1 to G.H.), the International Consortium for Brain Mapping (ICBM grant to K.Z.), the Willy Robert Pitzer Foundation (to G.H./W.H.O.) and the von behringlrontgenlstiftung (56-0039 to G.H.).
000005151 520__ $$aA dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT(2A)) receptor ligand [18F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT(2A) receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT(2A) receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.
000005151 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000005151 588__ $$aDataset connected to Web of Science, Pubmed
000005151 65320 $$2Author$$aPSP
000005151 65320 $$2Author$$aSteele-Richardson-Olszewski syndrome
000005151 65320 $$2Author$$aserotonin
000005151 65320 $$2Author$$a5-HT
000005151 65320 $$2Author$$a5-HT2A receptor
000005151 65320 $$2Author$$aPET
000005151 650_2 $$2MeSH$$aAged
000005151 650_2 $$2MeSH$$aBrain Mapping
000005151 650_2 $$2MeSH$$aCorpus Striatum: metabolism
000005151 650_2 $$2MeSH$$aCorpus Striatum: radionuclide imaging
000005151 650_2 $$2MeSH$$aFemale
000005151 650_2 $$2MeSH$$aFluorine Radioisotopes: metabolism
000005151 650_2 $$2MeSH$$aHumans
000005151 650_2 $$2MeSH$$aKetanserin: analogs & derivatives
000005151 650_2 $$2MeSH$$aKetanserin: metabolism
000005151 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000005151 650_2 $$2MeSH$$aMale
000005151 650_2 $$2MeSH$$aMiddle Aged
000005151 650_2 $$2MeSH$$aMovement Disorders: etiology
000005151 650_2 $$2MeSH$$aMovement Disorders: pathology
000005151 650_2 $$2MeSH$$aMovement Disorders: radionuclide imaging
000005151 650_2 $$2MeSH$$aPositron-Emission Tomography: methods
000005151 650_2 $$2MeSH$$aReceptor, Serotonin, 5-HT2A: metabolism
000005151 650_2 $$2MeSH$$aStatistics as Topic
000005151 650_2 $$2MeSH$$aSubstantia Nigra: metabolism
000005151 650_2 $$2MeSH$$aSubstantia Nigra: radionuclide imaging
000005151 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: complications
000005151 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: radionuclide imaging
000005151 650_2 $$2MeSH$$aUp-Regulation: physiology
000005151 650_7 $$00$$2NLM Chemicals$$aFluorine Radioisotopes
000005151 650_7 $$00$$2NLM Chemicals$$aReceptor, Serotonin, 5-HT2A
000005151 650_7 $$074050-98-9$$2NLM Chemicals$$aKetanserin
000005151 650_7 $$076330-71-7$$2NLM Chemicals$$aaltanserin
000005151 650_7 $$2WoSType$$aJ
000005151 7001_ $$0P:(DE-Juel1)138474$$aMatusch, A.$$b1$$uFZJ
000005151 7001_ $$0P:(DE-Juel1)131679$$aElmenhorst, D.$$b2$$uFZJ
000005151 7001_ $$0P:(DE-Juel1)VDB32531$$aHurlemann, R.$$b3$$uFZJ
000005151 7001_ $$0P:(DE-HGF)0$$aEggert, K.M.$$b4
000005151 7001_ $$0P:(DE-Juel1)131714$$aZilles, K.$$b5$$uFZJ
000005151 7001_ $$0P:(DE-HGF)0$$aOertel, W.H.$$b6
000005151 7001_ $$0P:(DE-HGF)0$$aHöglinger, G.U.$$b7
000005151 7001_ $$0P:(DE-Juel1)131672$$aBauer, A.$$b8$$uFZJ
000005151 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.22533$$gVol. 24, p. 1170 - 1175$$p1170 - 1175$$q24<1170 - 1175$$tMovement disorders$$v24$$x0885-3185$$y2009
000005151 8567_ $$uhttp://dx.doi.org/10.1002/mds.22533
000005151 909CO $$ooai:juser.fz-juelich.de:5151$$pVDB
000005151 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000005151 9141_ $$y2009
000005151 9131_ $$0G:(DE-Juel1)FUEK409$$aDE-HGF$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000005151 9201_ $$0I:(DE-Juel1)INM-2-20090406$$gINM$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000005151 9201_ $$0I:(DE-82)080010_20140620$$gJARA$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x1
000005151 970__ $$aVDB:(DE-Juel1)112593
000005151 980__ $$aVDB
000005151 980__ $$aConvertedRecord
000005151 980__ $$ajournal
000005151 980__ $$aI:(DE-Juel1)INM-2-20090406
000005151 980__ $$aI:(DE-82)080010_20140620
000005151 980__ $$aUNRESTRICTED
000005151 981__ $$aI:(DE-Juel1)VDB1046